The Results of Preoperative Chemoradiation Followed by Surgery on Rectal Cancer Patients Diagnosed MRF+ or T4b
S. Li,J. Jin,Y. Tang,N. Li,H. Ren,H. Fang,Y. W. Song,Y. Liu,S. Wang,B. Chen,S. Qi,N. Lu,Y. Li
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1001
2017-01-01
Abstract:To analyze the clinic outcomes of preoperative chemoradiotherapy (CRT) combined with surgery on rectal cancer patients with mesorectal fascia (MRF) involved by tumor infiltration or T4b. From January 2007 to November 2014, patients of rectal adenocarcinoma, who were diagnosed involved MRF by tumor infiltration (MRF+) or T4b based on pelvic MRI and undergone preoperative CRT, were in analysis. CRT followed by radical resection 6-8 weeks later was planned for all the patients, and adjuvant chemotherapy was delivered depending on postoperative recovery of patient and oncologist’s suggestion. A total of 111 eligible patients were enrolled in this study, with the median age 55 years (range: 24-82 years) and median distances 4 cm (range: 1-12 cm) from tumor edge to anal verge. Diagnosed by MRI, 48 patients (43.2%) were staged T4b and 63 cases (56.8%) with MRF+. Radiotherapy dose ranged from 44 to 50.4Gy (Median 50Gy), and concurrent capecitabine with or without oxaliplatin was administrated. In all, 74 patients (66.7%) received surgery after CRT (R0: 70, R1: 1, R2: 3). Among 37 cases who didn’t undergo surgery, 15 patients (13.5%) remained unresectable disease after CRT, 2 patients worried about high surgery risk, 14 patients refused to surgery because of private reasons, and 6 were found distant metastases before surgery. R0 resection rate was 63.1% for all the patients (T3 and MRF+: 73.0% vs. T4b: 50.0%, p=0.013).The median follow-up time was 45 months, 15 patients met local recurrences or progress, 36 patients undergone distant metastases. The 3-year OS and DM of all patients were 62.5% (R0: 76.7% vs. Non-R0: 37.8%, p<0.01) and 36.1% (R0: 28.6% vs. Non-R0: 50.9%, p=0.08), respectively. 57 patients died and the main cause of death was due to distant metastasis (76.9%). One third of rectal cancer patients with MRF+ or T4b still could not be resected radically even after chemoradiation, however patients with R0 resection would resulted in better survival. We should explore more effective treatment regimen for those patients, especially for cases of T4b.